Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:CASNumber |
1894093-42-9
|
| gptkbp:chemicalClass |
nucleotide
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2021)
|
| gptkbp:developedBy |
gptkb:Atea_Pharmaceuticals
gptkb:Roche |
| gptkbp:hasMolecularFormula |
C22H32N6O7S
|
| https://www.w3.org/2000/01/rdf-schema#label |
AT-527
|
| gptkbp:intendedUse |
treatment of COVID-19
|
| gptkbp:mechanismOfAction |
RNA polymerase inhibitor
|
| gptkbp:prodrugOf |
AT-9010
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
bemnifosbuvir
|
| gptkbp:target |
gptkb:COVID-19
gptkb:Hepatitis_C_virus |
| gptkbp:bfsParent |
gptkb:Atea_Pharmaceuticals
|
| gptkbp:bfsLayer |
8
|